Stellaromics Taps Biotech Veterans to Lead Spatial Biology Charge

BOSTON, MA – February 10, 2026 – In a strategic move poised to accelerate its commercial ambitions, 3D spatial multi-omics pioneer Stellaromics today announced the appointment of two industry heavyweights, Dr. Stacie Weninger and Steve McPhail, to its Board of Directors. The appointments come as the company prepares to scale its innovative Pyxa™ spatial platform, a technology designed to provide an unprecedented three-dimensional view of biological tissue.

The addition of Dr. Weninger, a neuroscience expert and Venture Partner at F-Prime Capital, and Mr. McPhail, a seasoned commercial executive with a long track record in genomics, signals a clear intent to fuse deep scientific credibility with proven market-scaling expertise. This dual-pronged approach is designed to fortify Stellaromics' position in the fiercely competitive and rapidly expanding spatial biology market.

"We are incredibly honored to welcome Stacie and Steve to Stellaromics' Board of Directors at this transformative stage of our journey," said Todd Dickinson, CEO of Stellaromics, in a statement. "Stacie's deep scientific roots and Steve's unparalleled experience in commercializing genomic technologies provide the perfect blend of insights to guide our mission. Their collective wisdom will be a powerful catalyst as we empower scientists to unlock the next frontier of spatial biology."

A Strategic Play in a High-Stakes Market

The appointments are not just a routine corporate update; they represent a calculated maneuver in the high-stakes arena of life science tools. The spatial multi-omics market, valued at over $1.15 billion in 2025, is on a steep growth trajectory, with some analysts projecting it will surpass $2.8 billion by 2032. This growth is fueled by the technology's promise to revolutionize drug development and precision medicine by mapping molecular activity within the context of tissue architecture.

Stellaromics enters this dynamic field with a key differentiator: its focus on true 3D analysis. While competitors like 10x Genomics, Bruker (which acquired NanoString Technologies in 2024), and Vizgen have established strong footholds with powerful 2D spatial platforms, their technologies primarily analyze thin tissue slices. This can cause researchers to miss critical cellular interactions and architectural features that exist across multiple layers. Stellaromics' Pyxa™ platform is engineered to overcome this limitation by analyzing tissue samples up to 100μm thick or more, offering what it claims is a 10-20x improvement in volumetric analysis.

By adding Mr. McPhail, who previously led Expression Analysis to a successful acquisition by Quintiles (now IQVIA) and managed global commercial operations at Fluidigm, Stellaromics is arming itself with the leadership needed to translate this technological advantage into market share. His experience is critical for navigating a landscape dominated by established players and for building the commercial infrastructure required for global reach.

Fueling the Pyxa Engine for Scientific Breakthroughs

At the heart of the company's strategy is the Pyxa™ platform itself. Unveiled in early 2025, the system is a high-plex, confocal instrument that generates fully annotated, single-cell maps of gene expression in three dimensions. It leverages proprietary 3D probe chemistries, including technologies like STARmap and RIBOmap, to simultaneously detect hundreds to thousands of genes at sub-cellular resolution, all while preserving the native tissue structure.

This capability is particularly transformative for complex research areas like oncology and neuroscience. In October 2025, the company installed its first external beta unit at the University of Glasgow to study the intricate tumor microenvironment in cancer. Researchers there are leveraging Pyxa's 3D capabilities to map cellular neighborhoods and interactions that are often lost in 2D analysis, potentially revealing new targets for therapy.

The appointment of Dr. Weninger directly reinforces this scientific mission. With over 20 years of experience in neuroscience, her expertise will be invaluable in guiding the application of the Pyxa™ platform to one of biology's most complex challenges: understanding the brain. The ability to map neural networks and cellular function across three dimensions is a long-sought-after goal in the field, and Dr. Weninger's guidance will help Stellaromics align its technological development with the most pressing needs of CNS researchers.

The Vision and Venture Capital Attracting Top Talent

That Stellaromics can attract leaders of this caliber speaks volumes about its perceived potential. The company is not a fledgling startup running on fumes; it is a well-capitalized, high-growth enterprise. In February 2025, it closed an $80 million Series B funding round led by Catalyst4, bringing its total funding to an estimated $105 million. This financial backing has fueled significant expansion, with the company reportedly increasing its employee count by 150% over the past year.

Dr. Weninger's presence on the board, given her role as a Venture Partner at F-Prime Capital, also serves as a powerful endorsement of the company's technology and long-term vision. Venture firms like F-Prime are tasked with identifying companies capable of delivering not just financial returns but also paradigm-shifting scientific advancements. Her decision to join the board suggests a high degree of confidence in Stellaromics' ability to do both.

Mr. McPhail's career, marked by successfully scaling genomics organizations, provides a complementary perspective. For seasoned executives, the opportunity to help build the next market-defining company is a powerful draw. The combination of disruptive technology, a massive addressable market, and strong financial backing creates a compelling narrative that attracts top-tier talent seeking to make a significant impact. Stellaromics appears to have successfully woven this narrative, positioning itself as a destination for leaders looking to shape the future of biological research.